A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic Clinical Trial

Official title:

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC Injection in Adult Participants With Moderate to Severe Atopic Dermatitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05999799
• Other study ID #: 219538
• Secondary ID: 2023-505414-15-0
• Status: Recruiting
• Phase: Phase 2
• Start date: November 16, 2023
• Est. completion date: June 25, 2025

Study information

• Verified date: June 2024
• Source: GlaxoSmithKline
• Contact: US GSK Clinical Trials Call Center
• Phone: 877-379-3718
• Email: GSKClinicalSupportHD[@]gsk.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 175
• Est. completion date: June 25, 2025
• Est. primary completion date: April 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Adult participants 18 years to 75 years of age

• Participants with:

• AtD defined by the AAD Consensus Criteria.

• Diagnosis of AtD =1 year.

• An IGA score =3.

• AtD involvement of =10% body surface area (BSA).

• EASI score =16

• Baseline pruritus numerical rating scale average score for maximum intensity of at least 3.

• Participants may have had exposure to 1 biologic therapy meeting at least 1 of the following conditions:

• Participants who stopped treatment due to non-response, partial response, loss of efficacy.

• Participants who stopped treatment due to intolerance or AEs.

• Participants who stopped treatment due to cost or loss of access.

• Participant with a recent history less than or equal to (=6) months prior to the Screening visit) of inadequate response to a stable regimen of prescription topical medication.

• Participants for whom prescription topical medications are not tolerated.

• Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical study

Exclusion Criteria:

• Chronic or acute infection requiring treatment with oral or IV antibiotics, antivirals, anti-protozoal, or antifungals within 4 weeks before the Screening visit or anytime between the Screening and Baseline visits.

• Superficial skin infections within 1 week before the Screening visit or active infections (including localized infections), or history of recurrent infections (excluding recurrent fungal infections of the nail bed)

• Known, pre-existing or suspected parasitic infection within 6 months before the Screening visit.

• Symptomatic herpes zoster within 3 months prior to screening

• Uncontrolled hypertension.

• Current or chronic history of liver disease or known hepatic or biliary abnormalities.

• Known or suspected history of immunosuppression, including history of invasive opportunistic infections despite infection resolution or unusually frequent, recurrent, or prolonged infections, per the Investigator's judgment.

• Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years

• Breast cancer within the past 10 years.

• History or presence of significant medical illness including but not limited to cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurological, or psychiatric disorders which in the opinion of the investigator would interfere with the study procedures and/or assessments.

• Previously treated with any oral Janus Kinase inhibitor (JAKi) or other kinase inhibitors, experimental or approved.

• Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma.

• Presence of Hepatitis B surface antibody (HBsAg) or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention.

• Positive hepatitis C antibody test result at screening or within 3 months prior to starting study intervention.

• Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.

• Positive HIV antibody test.

• Evidence of active or latent TB as documented by medical history, examination, and TB testing with a positive QuantiFERON test at initial Screening visit.

• Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.

Related Conditions & MeSH terms

• Dermatitis
• Dermatitis, Atopic

Intervention

Drug:
• GSK1070806
GSK1070806 will be administered.
• Placebo
Placebo will be administered.

Locations

Country	Name	City	State
Argentina	GSK Investigational Site	Caba	Buenos Aires
Argentina	GSK Investigational Site	Ciudad Autonoma de Buenos Aires	Buenos Aires
Argentina	GSK Investigational Site	Ciudad Autonoma de Buenos Aires	Buenos Aires
Argentina	GSK Investigational Site	Cordoba	Córdova
Argentina	GSK Investigational Site	Mendoza
Argentina	GSK Investigational Site	Rosario	Santa Fe
Bulgaria	GSK Investigational Site	Pleven
Bulgaria	GSK Investigational Site	Sofia
Bulgaria	GSK Investigational Site	Sofia
Canada	GSK Investigational Site	Barrie	Ontario
Canada	GSK Investigational Site	London	Ontario
Canada	GSK Investigational Site	Markham	Ontario
Canada	GSK Investigational Site	Quebec
China	GSK Investigational Site	Beijing
China	GSK Investigational Site	Chongqing	Chongqing
China	GSK Investigational Site	Fu Zhou
China	GSK Investigational Site	Guangzhou
China	GSK Investigational Site	Hangzhou
China	GSK Investigational Site	Shanghai
China	GSK Investigational Site	Shanghai	Shanghai
China	GSK Investigational Site	Yinchuan
China	GSK Investigational Site	Yiwu City	Zhejiang
Czechia	GSK Investigational Site	Pardubice
Czechia	GSK Investigational Site	Prague
Czechia	GSK Investigational Site	Praha
Czechia	GSK Investigational Site	Praha 2
France	GSK Investigational Site	La Rochelle cedex 1
France	GSK Investigational Site	Nice
France	GSK Investigational Site	Paris cedex 10
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Essen	Nordrhein-Westfalen
Germany	GSK Investigational Site	Hamburg
Germany	GSK Investigational Site	Kiel	Schleswig-Holstein
Germany	GSK Investigational Site	Muenster	Nordrhein-Westfalen
Greece	GSK Investigational Site	Athens
Greece	GSK Investigational Site	Thessaloniki
Italy	GSK Investigational Site	Bari
Italy	GSK Investigational Site	Bologna	Emilia Romagna
Italy	GSK Investigational Site	Firenze
Italy	GSK Investigational Site	Modena	Emilia-Romagna
Italy	GSK Investigational Site	Roma	Lazio
Italy	GSK Investigational Site	Roma
Japan	GSK Investigational Site	Chiba
Japan	GSK Investigational Site	Chiba
Japan	GSK Investigational Site	Fukuoka
Japan	GSK Investigational Site	Fukuoka
Japan	GSK Investigational Site	Gunma
Japan	GSK Investigational Site	Hokkaido
Japan	GSK Investigational Site	Hokkaido
Japan	GSK Investigational Site	Kanagawa
Japan	GSK Investigational Site	Osaka
Japan	GSK Investigational Site	Osaka
Japan	GSK Investigational Site	Saitama
Korea, Republic of	GSK Investigational Site	Gyeonggi-do
Korea, Republic of	GSK Investigational Site	Seoul
Korea, Republic of	GSK Investigational Site	Seoul
Korea, Republic of	GSK Investigational Site	Seoul
Korea, Republic of	GSK Investigational Site	Seoul
Mexico	GSK Investigational Site	Chihuahua
Mexico	GSK Investigational Site	Durango.	Durango
Mexico	GSK Investigational Site	Guadalajara	Jalisco
Mexico	GSK Investigational Site	Monterrey
Panama	GSK Investigational Site	Ciudad de Panama
Poland	GSK Investigational Site	Chojnice
Poland	GSK Investigational Site	Elblag
Poland	GSK Investigational Site	Katowice
Poland	GSK Investigational Site	Poznan
Poland	GSK Investigational Site	Szczecin
Poland	GSK Investigational Site	Warsaw
Spain	GSK Investigational Site	Alicante
Spain	GSK Investigational Site	Córdoba
Spain	GSK Investigational Site	Granada
Spain	GSK Investigational Site	Majadahonda	Madrid
Spain	GSK Investigational Site	Valencia
Spain	GSK Investigational Site	Vigo	Pontevedra
Spain	GSK Investigational Site	Zaragoza
Thailand	GSK Investigational Site	Bangkok	Pathum Wan
Thailand	GSK Investigational Site	Khlong Luang
United States	GSK Investigational Site	Canoga Park	California
United States	GSK Investigational Site	Dublin	Ohio
United States	GSK Investigational Site	Fayetteville	Georgia
United States	GSK Investigational Site	Fountain Valley	California
United States	GSK Investigational Site	Methuen	Massachusetts
United States	GSK Investigational Site	New York	New York
United States	GSK Investigational Site	New York	New York
United States	GSK Investigational Site	North Little Rock	Arkansas
United States	GSK Investigational Site	Phoenix	Arizona
United States	GSK Investigational Site	Pompano Beach	Florida
United States	GSK Investigational Site	Santa Monica	California
United States	GSK Investigational Site	Springville	Utah
United States	GSK Investigational Site	Thomasville	Georgia
United States	GSK Investigational Site	Troy	Michigan
United States	GSK Investigational Site	W. Lake Hills	Texas

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Argentina,  Bulgaria,  Canada,  China,  Czechia,  France,  Germany,  Greece,  Italy,  Japan,  Korea, Republic of,  Mexico,  Panama,  Poland,  Spain,  Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change from Baseline (PCFB) in the Eczema Area and Severity Index (EASI) at Week 16	EASI is an internationally used classification for AtD severity and an investigator-assessed measure that is used to assess the extent (area) and severity of AtD. The range of the scale is 0-72, with a higher score indicating greater severity.	Baseline and Week 16
Secondary	Percent Change from Baseline (PCFB) EASI Score for GSK1070806 at Each Time Point	EASI score percent changes from baseline at each time point will be reported. EASI is an internationally used classification for AtD severity and an investigator-assessed measure that is used to assess the extent (area) and severity of AtD. The range of the scale is 0-72, with a higher score indicating greater severity.	Baseline and up to Week 28
Secondary	Number of Participants Achieving EASI Reduction of Greater than or Equal to (=) 75 Percentage (%) from Baseline at Week 16	The occurrence of =75% reduction from baseline achieving EASI75 score at Week 16 will be reported. EASI is an internationally used classification for AtD severity and an investigator-assessed measure that is used to assess the extent (area) and severity of AtD. The range of the scale is 0-72, with a higher score indicating greater severity.	Baseline and Week 16
Secondary	Number of Participants Achieving Investigator's Global Assessment (IGA) score of 0 or 1 at Week 16	IGA for AtD is a measure of overall disease severity at the time of assessment on a 5-point scale by the investigator. Where 0-clear, 1-almost clear, 2-mild disease, 3-moderate disease, and 4- severe disease. Higher score indicates severity of disease. A participant with an IGA score of 0 or 1 from baseline will be reported.	Up to Week 16
Secondary	Change from Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) Score at Week 16	PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values will be evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch.	Baseline and Week 16
Secondary	Number of Participants Achieving PP-NRS Reduction of =4 points from Baseline at Week. 16	Participants achieving a reduction of =4 points from baseline of peak pruritus NRS score at Week 16 will be reported. The values will be evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch.	Baseline and Week 16
Secondary	Number of Participants Achieving EASI Reduction of =50% or 90% or 100% from Baseline at Week 16	The occurrence of =50% or 90% or 100% reduction from baseline achieving EASI score at Week 16 will be reported. EASI is an internationally used classification for AtD severity and an investigator-assessed measure that is used to assess the extent (area) and severity of AtD. The range of the scale is 0-72, with a higher score indicating greater severity.	Baseline and Week 16
Secondary	Number of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Reduction of = 50% or 75% from Baseline at Week 16	Participants achieving a reduction SCORAD reduction of 50% or 75% from Baseline will be reported. SCORAD is a clinical tool to assess the extent and severity of AtD with 3 components. The total score for SCORAD index formula is computed as formula A is defined as the extent (0-100), B is defined as the intensity (0-18) and C is defined as the subjective symptoms (0-20). The total SCORAD score ranges from 0 (no disease) to 103 (severe disease).	Baseline and Week 16
Secondary	Change from Baseline in the Body surface area (BSA) of GSK1070806 at Week 16	The BSA assessment estimates the extent of disease or skin involvement with respect to AtD and is expressed as a percentage of total body surface. BSA will be determined by the Investigator or designee using the patient palm = 1% rule	Baseline and Week 16
Secondary	Change from Baseline in the SCORAD of GSK1070806 at Week 16	SCORAD is a clinical tool to assess the extent and severity of AtD with 3 components. The total score for SCORAD index formula is computed as formula A is defined as the extent (0-100), B is defined as the intensity (0-18) and C is defined as the subjective symptoms (0-20). The total SCORAD score ranges from 0 (no disease) to 103 (severe disease).	Baseline and Week 16
Secondary	Change from Baseline in Patient Reported Outcomes (PRO) Measure of Skin Pain Numerical Rating Scale (SP-NRS) at Week 16	SP-NRS is a patient reported measure assessing worst level of skin pain (in the past 24 hours). The values will be evaluated using an 11-point scale from 0 to 10, with 0 being no pain and 10 being the worst pain imaginable.	Baseline and Week 16
Secondary	Change from Baseline in PRO Measure of Patient Reported Outcomes Measurement Information System (PROMIS) -Sleep Disturbance 8b at Week 16	The PROMIS Short Form Sleep disturbance 8b is a PRO instrument designed to assess self-reported sleep disturbance for which the recall period is the past 7 days. The items are rated on a 5-point verbal rating scale. Items are summed giving a range in raw score from 8 to 40, with higher scores indicating greater severity of sleep disturbance.	Baseline and Week 16
Secondary	Change from Baseline in PRO Measure of Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue at Week 16	The FACIT-Fatigue scale is a short, 13-item measure that assesses self-reported fatigue and its associated impact for daily activities over the past week. The items are rated on a 5-point Likert-type scale (i.e., 4 = not at all to 0 = very much). The scale range is 0 to 52, with 0 being the worst possible score and 52 indicating no fatigue.	Baseline and Week 16
Secondary	Change from Baseline in PRO Measure of Brief Fatigue Inventory (BFI) - Item 3 at Week 16	The BFI is a self-administered questionnaire developed to assess fatigue severity. The BFI has 9 items. BFI item 3 assesses the worst level of fatigue related concepts (i.e., tiredness, weariness) during the past 24 hours. Participants report their worst level of fatigue daily, for the previous 24 hours, using a numerical rating scale ranging from 0 (no fatigue) to 10 (as bad as you can imagine).	Baseline and Week 16
Secondary	Change from Baseline in PRO Measure of Patient Oriented Eczema Measure (POEM) at Week 16	POEM is a 7-item questionnaire that assesses symptoms of dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping over the last week. The scoring symptom ranges from 0 (absent disease) to 28 (severe disease). Higher score indicates poor QoL.	Baseline and Week 16
Secondary	Change from Baseline in PRO Measure of Dermatology Life Quality Index (DLQI) at Week 16	The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that their skin disease has affected their QoL. It is calculated by summing the scores of the 10 questions, ranging from 0 to 30 with higher scores indicating more impaired QoL. A score of 0 or 1 means that the disease has no effect at all.	Baseline and Week 16
Secondary	Change from Baseline in PRO Measure of Hospital Anxiety and Depression Scale (HADS) at Week 16	The HADS is a self-reported questionnaire which measures depression and generalized anxiety, in the past week. Each item on the questionnaire ranges from 0 (no, not at all) to 3 (yes, definitely). The scale ranges from 0 to 21, with lower score indicating better QoL.	Baseline and Week 16
Secondary	Change from Baseline in PRO Measure of Work Productivity and Activity Impairment Questionnaire-Atopic Dermatitis (WPAI- AD) at Week 16	The WPAI-AD is a validated, patient-reported, quantitative assessment of absenteeism (work time missed), presentism (reduced on-the-job effectiveness), work productivity loss and activity impairment due to a specific health problem.	Baseline and Week 16
Secondary	Occurrences of Adverse Events (AEs), Serious AE (SAEs), and AEs of Special Interest (AESI)	AEs, SAEs, and AESIs will be reported. An AE is any untoward medical occurrence in participant, temporally associated with use of study intervention, whether or not considered related to medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, medically important were categorized as SAE. AESIs of the study drug includes serious and opportunistic infections, serious hypersensitivity reactions and Injection site reactions.	Up to Week 28
Secondary	Change from Baseline in Haematology Parameter: Haemoglobin (Hb) (Grams per Litre)		Baseline and Up to Week 28
Secondary	Change from Baseline in Haematology Parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, White Blood Cell (WBC), and Platelet Count (Giga Cells per Litre)		Baseline and Up to Week 28
Secondary	Change from Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Gamma-Glutamyl Transferase (GGT), and Alkaline Phosphatase (AP) (Units per Litre)		Baseline and Up to Week 28
Secondary	Change From Baseline in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST) (International Units per Litre)		Baseline and Up to Week 28
Secondary	Change from Baseline in Clinical Chemistry Parameter: Total Bilirubin (Micromoles per Litre)		Baseline and Up to Week 28
Secondary	Number of Participants with Greater than or Equal to (=) Grade 3 Hematological/Clinical Chemistry Abnormalities According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE)	Hematological/clinical chemistry abnormalities summarized according to NCI CTCAE grade.	Up to Week 28